CorMedix Company Profile (NYSEMKT:CRMD)

About CorMedix (NYSEMKT:CRMD)

CorMedix logoCorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications. Neutrolin is an anti-infective solution for the prevention of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. Neutrolin is a broad-spectrum antimicrobial/antifungal and anticoagulant combination that is active against common microbes, including antibiotic-resistant strains, and may prevent biofilm formation.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:CRMD
  • CUSIP: N/A
  • Web: N/A
Capitalization:
  • Market Cap: $17.31 million
  • Outstanding Shares: 40,323,000
Average Prices:
  • 50 Day Moving Avg: $0.76
  • 200 Day Moving Avg: $1.57
  • 52 Week Range: $0.40 - $3.26
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.99
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $222,237.00
  • Price / Sales: 77.11
  • Book Value: $0.27 per share
  • Price / Book: 1.57
Profitability:
  • EBIDTA: ($28,200,000.00)
Misc:
  • Average Volume: 385,511 shs.
  • Beta: 0.24
  • Short Ratio: 10.7
 

Frequently Asked Questions for CorMedix (NYSEMKT:CRMD)

What is CorMedix's stock symbol?

CorMedix trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "CRMD."

How were CorMedix's earnings last quarter?

CorMedix Inc. (NYSEMKT:CRMD) announced its quarterly earnings results on Wednesday, November, 9th. The company reported ($0.23) EPS for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.08. The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.05 million. View CorMedix's Earnings History.

Where is CorMedix's stock going? Where will CorMedix's stock price be in 2017?

2 analysts have issued twelve-month price objectives for CorMedix's shares. Their forecasts range from $4.00 to $5.00. On average, they expect CorMedix's share price to reach $4.50 in the next twelve months. View Analyst Ratings for CorMedix.

Who are some of CorMedix's key competitors?

Who owns CorMedix stock?

CorMedix's stock is owned by many different of institutional and retail investors. Top institutional investors include Elliott Management Corp (3.68%), Vanguard Group Inc. (2.91%), Bollard Group LLC (1.00%), Geode Capital Management LLC (0.45%), Ray Gerald L & Associates Ltd. (0.39%) and Private Advisor Group LLC (0.22%). Company insiders that own CorMedix stock include Antony Pfaffle, Cora M Tellez, Janet Dillione, Khoso Baluch, Matthew Duffy, Randy Milby, Robert W Cook, Steven W Lefkowitz and Taunia Markvicka. View Institutional Ownership Trends for CorMedix.

Who sold CorMedix stock? Who is selling CorMedix stock?

CorMedix's stock was sold by a variety of institutional investors in the last quarter, including Ray Gerald L & Associates Ltd. and Private Advisor Group LLC. Company insiders that have sold CorMedix stock in the last year include Antony Pfaffle, Matthew Duffy and Steven W Lefkowitz. View Insider Buying and Selling for CorMedix.

Who bought CorMedix stock? Who is buying CorMedix stock?

CorMedix's stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. Company insiders that have bought CorMedix stock in the last two years include Cora M Tellez, Janet Dillione, Khoso Baluch, Randy Milby, Robert W Cook and Taunia Markvicka. View Insider Buying and Selling for CorMedix.

How do I buy CorMedix stock?

Shares of CorMedix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of CorMedix stock cost?

One share of CorMedix stock can currently be purchased for approximately $0.43.

Analyst Ratings

Consensus Ratings for CorMedix (NYSEMKT:CRMD) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.50

Analysts' Ratings History for CorMedix (NYSEMKT:CRMD)
Show:
DateFirmActionRatingPrice TargetDetails
5/5/2017Rodman & RenshawLower Price TargetBuy$6.00 -> $5.00View Rating Details
4/24/2017FBR & CoReiterated RatingBuyView Rating Details
11/16/2015Roth CapitalLower Price TargetNeutral$2.75 -> $2.50View Rating Details
11/12/2015HC WainwrightInitiated CoverageBuy$6.50View Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for CorMedix (NYSEMKT:CRMD)
Earnings by Quarter for CorMedix (NYSEMKT:CRMD)
Earnings History by Quarter for CorMedix (NYSEMKT:CRMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2016Q3 2016($0.15)($0.23)$0.05 million$0.04 millionViewN/AView Earnings Details
8/5/2016Q216($0.11)($0.13)$119.97 million$16.51 millionViewN/AView Earnings Details
5/10/2016Q1($0.09)($0.12)$0.11 million$0.04 millionViewN/AView Earnings Details
11/12/2015Q3($0.13)($0.14)$0.12 million$0.04 millionViewListenView Earnings Details
8/6/2015Q2 2015($0.13)($0.13)$0.08 million$0.12 millionViewN/AView Earnings Details
3/12/2015Q4 2014($0.12)($0.09)$0.08 million$0.09 millionViewN/AView Earnings Details
11/13/2014Q3 2014($0.09)($0.09)$0.08 million$0.05 millionViewN/AView Earnings Details
8/14/2014Q2 2014($0.13)($0.26)$0.02 million$0.04 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CorMedix (NYSEMKT:CRMD)
Current Year EPS Consensus Estimate: $-0.640 EPS
Next Year EPS Consensus Estimate: $-0.430 EPS

Dividends

Dividend History for CorMedix (NYSEMKT:CRMD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for CorMedix (NYSEMKT:CRMD)
Insider Trades by Quarter for CorMedix (NYSEMKT:CRMD)
Institutional Ownership by Quarter for CorMedix (NYSEMKT:CRMD)
Insider Trades by Quarter for CorMedix (NYSEMKT:CRMD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/17/2017Khoso BaluchCEOBuy75,000$0.48$36,000.00View SEC Filing  
5/16/2017Cora M TellezDirectorBuy50,000$0.48$24,000.00View SEC Filing  
5/15/2017Janet DillioneDirectorBuy21,231$0.48$10,190.88View SEC Filing  
5/15/2017Robert W CookCFOBuy50,000$0.50$25,000.00View SEC Filing  
5/1/2017Cora M TellezDirectorBuy4,800$0.66$3,168.00View SEC Filing  
3/30/2017Cora M TellezDirectorBuy1,950$1.66$3,237.00View SEC Filing  
2/28/2017Cora M TellezDirectorBuy1,540$2.10$3,234.00View SEC Filing  
2/7/2017Antony PfaffleInsiderSell10,000$2.00$20,000.00View SEC Filing  
1/30/2017Cora M TellezDirectorBuy1,780$1.79$3,186.20View SEC Filing  
12/30/2016Cora M TellezDirectorBuy1,990$1.58$3,144.20View SEC Filing  
12/9/2016Khoso BaluchCEOBuy10,000$1.77$17,700.00View SEC Filing  
11/30/2016Cora M TellezDirectorBuy1,800$1.80$3,240.00View SEC Filing  
10/31/2016Cora M TellezDirectorBuy1,475$2.15$3,171.25View SEC Filing  
10/21/2016Antony PfaffleInsiderSell20,000$2.23$44,600.00View SEC Filing  
9/22/2016Janet DillioneDirectorBuy15,000$2.66$39,900.00View SEC Filing  
8/25/2016Taunia MarkvickaDirectorBuy18,600$1.65$30,690.00View SEC Filing  
8/19/2016Cora M TellezDirectorBuy12,500$1.73$21,625.00View SEC Filing  
6/21/2016Antony PfaffleInsiderSell29,657$2.14$63,465.98View SEC Filing  
6/20/2016Antony PfaffleInsiderSell10,000$2.16$21,600.00View SEC Filing  
6/15/2016Antony PfaffleInsiderSell4,900$2.21$10,829.00View SEC Filing  
6/13/2016Antony PfaffleInsiderSell5,443$2.27$12,355.61View SEC Filing  
6/9/2016Antony PfaffleInsiderSell10,000$2.38$23,800.00View SEC Filing  
6/8/2016Janet DillioneDirectorBuy3,738$2.67$9,980.46View SEC Filing  
6/3/2016Matthew DuffyDirectorSell46,106$2.73$125,869.38View SEC Filing  
5/31/2016Steven W LefkowitzDirectorSell50,000$2.88$144,000.00View SEC Filing  
5/25/2016Cora M TellezDirectorBuy8,600$2.90$24,940.00View SEC Filing  
5/24/2016Antony PfaffleInsiderSell12,700$2.73$34,671.00View SEC Filing  
5/24/2016Antony PfaffleInsiderSell12,700$2.73$34,671.00View SEC Filing  
5/23/2016Antony PfaffleInsiderSell15,000$2.89$43,350.00View SEC Filing  
5/23/2016Steven W LefkowitzDirectorSell30,000$2.93$87,900.00View SEC Filing  
5/19/2016Antony PfaffleInsiderSell12,300$2.82$34,686.00View SEC Filing  
5/16/2016Antony PfaffleInsiderSell60,000$2.68$160,800.00View SEC Filing  
6/30/2015Randy MilbyCEOBuy1,610$3.88$6,246.80View SEC Filing  
6/23/2015Taunia MarkvickaDirectorBuy4,000$4.81$19,240.00View SEC Filing  
6/15/2015Randy MilbyCEOBuy1,245$5.02$6,249.90View SEC Filing  
6/4/2015Matthew DuffyDirectorSell30,000$6.48$194,400.00View SEC Filing  
5/29/2015Randy MilbyCEOBuy1,026$6.09$6,248.34View SEC Filing  
2/27/2015Randy MilbyCEOBuy1,211$5.16$6,248.76View SEC Filing  
2/13/2015Randy MilbyCEOBuy1,911$3.27$6,248.97View SEC Filing  
1/30/2015Randy MilbyCEOBuy2,016$3.10$6,249.60View SEC Filing  
12/15/2014Randy MilbyCEOBuy4,734$1.32$6,248.88View SEC Filing  
11/28/2014Randy MilbyCEOBuy4,464$1.40$6,249.60View SEC Filing  
11/14/2014Cora M TellezDirectorBuy11,086$1.52$16,850.72View SEC Filing  
11/14/2014Randy MilbyCEOBuy4,111$1.52$6,248.72View SEC Filing  
10/31/2014Randy MilbyCEOBuy3,434$1.82$6,249.88View SEC Filing  
9/30/2014Randy MilbyCEOBuy3,324$1.88$6,249.12View SEC Filing  
9/15/2014Randy MilbyCEOBuy3,654$1.71$6,248.34View SEC Filing  
8/29/2014Randy MilbyCEOBuy3,125$2.00$6,250.00View SEC Filing  
8/15/2014Randy MilbyCEOBuy3,140$1.99$6,248.60View SEC Filing  
7/31/2014Randy MilbyCEOBuy6,250$2.00$12,500.00View SEC Filing  
6/30/2014Randy MilbyCEOBuy2,732$1.83$4,999.56View SEC Filing  
12/13/2013Steven W LefkowitzInsiderBuy18,000$0.78$14,040.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for CorMedix (NYSEMKT:CRMD)
Latest Headlines for CorMedix (NYSEMKT:CRMD)
Source:
DateHeadline
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of CorMedix, Inc.
finance.yahoo.com - May 26 at 5:00 PM
finance.yahoo.com logoETFs with exposure to CorMedix, Inc. : May 26, 2017
finance.yahoo.com - May 26 at 5:00 PM
americanbankingnews.com logoCorMedix Inc. (CRMD) CEO Purchases $36,000.00 in Stock
www.americanbankingnews.com - May 19 at 8:52 PM
americanbankingnews.com logoCorMedix Inc. (CRMD) CFO Acquires $25,000.00 in Stock
www.americanbankingnews.com - May 17 at 8:34 PM
americanbankingnews.com logoCorMedix Inc. (CRMD) Director Cora M. Tellez Buys 50,000 Shares
www.americanbankingnews.com - May 17 at 8:34 PM
americanbankingnews.com logoCorMedix Inc. (CRMD) Director Janet Dillione Buys 21,231 Shares
www.americanbankingnews.com - May 17 at 8:34 PM
americanbankingnews.com logoZacks Investment Research Downgrades CorMedix Inc. (CRMD) to Hold
www.americanbankingnews.com - May 15 at 8:58 PM
finance.yahoo.com logoETFs with exposure to CorMedix, Inc. : May 15, 2017
finance.yahoo.com - May 15 at 4:23 PM
finance.yahoo.com logoCorMedix, Inc. :CRMD-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
finance.yahoo.com - May 12 at 5:02 PM
finanznachrichten.de logoCormedix, Inc.: CorMedix Inc. Reports First Quarter Financial Results and Provides Business Update
www.finanznachrichten.de - May 10 at 9:43 PM
finance.yahoo.com logoCorMedix Inc. Reports First Quarter Financial Results and Provides Business Update
finance.yahoo.com - May 10 at 4:40 PM
finance.yahoo.com logoCorMedix Inc. Demonstrates Sensitivity of Emerging Global Health Threat Candida auris to Taurolidine
finance.yahoo.com - May 9 at 4:28 PM
finance.yahoo.com logoCorMedix Inc. to Report First Quarter 2017 Financial Results and Provide Business Update
finance.yahoo.com - May 5 at 4:43 PM
americanbankingnews.com logoRodman & Renshaw Cuts CorMedix Inc. (CRMD) Price Target to $5.00
www.americanbankingnews.com - May 5 at 8:36 AM
americanbankingnews.com logoCorMedix (CRMD) Earning Somewhat Favorable Media Coverage, Report Shows
www.americanbankingnews.com - May 4 at 1:46 PM
finance.yahoo.com logoCorMedix Inc. Announces Closing of Public Offering of Common Stock and Warrants and Underwriter's Exercise in Full of Over-Allotment Option
finance.yahoo.com - May 3 at 9:28 PM
finance.yahoo.com logoImplied Volatility Surging for CorMedix (CRMD) Stock Options
finance.yahoo.com - May 1 at 4:25 PM
americanbankingnews.com logoVery Favorable Media Coverage Extremely Likely to Affect CorMedix (CRMD) Share Price
www.americanbankingnews.com - May 1 at 10:44 AM
finance.yahoo.com logoCorMedix Inc. Increases Previously Announced Public Offering to $12.1 Million
finance.yahoo.com - April 28 at 5:27 PM
finance.yahoo.com logoCorMedix Inc. Announces $10 Million Underwritten Public Offering
finance.yahoo.com - April 27 at 10:00 PM
americanbankingnews.com logoPositive Media Coverage Unlikely to Impact CorMedix (CRMD) Stock Price
www.americanbankingnews.com - April 27 at 5:22 PM
americanbankingnews.com logoCorMedix Inc. (CRMD) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 25 at 8:52 PM
americanbankingnews.com logoFBR & Co Reaffirms "Buy" Rating for CorMedix Inc. (CRMD)
www.americanbankingnews.com - April 25 at 4:17 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of CorMedix, Inc.
finance.yahoo.com - April 25 at 12:02 PM
americanbankingnews.com logoCorMedix (CRMD) Getting Favorable News Coverage, Report Shows
www.americanbankingnews.com - April 24 at 3:36 PM
finance.yahoo.com logoCorMedix Inc. Reports Update on Neutrolin(R) Phase 3 LOCK-IT 100 Clinical Trial
finance.yahoo.com - April 20 at 4:39 PM
americanbankingnews.com logoCorMedix (CRMD) Given News Impact Rating of 0.44
www.americanbankingnews.com - April 20 at 7:50 AM
americanbankingnews.com logoCorMedix (CRMD) Receives Daily Coverage Optimism Rating of 0.56
www.americanbankingnews.com - April 14 at 10:52 AM
finance.yahoo.com logoCorMedix Inc. Secures First European Commercial Collaboration for Neutrolin(R)
finance.yahoo.com - April 12 at 4:30 PM
finance.yahoo.com logoETFs with exposure to CorMedix, Inc. : April 10, 2017
finance.yahoo.com - April 10 at 4:21 PM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in CorMedix (CRMD) Stock?
finance.yahoo.com - March 30 at 4:56 PM
americanbankingnews.com logoCorMedix Inc. (CRMD) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - March 27 at 9:02 AM
finance.yahoo.com logoCorMedix Inc. Makes NYSE MKT Section 610(b) Public Announcement
finance.yahoo.com - March 23 at 9:58 PM
americanbankingnews.com logoCorMedix Inc. (CRMD) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - March 21 at 7:33 PM
seekingalpha.com logoCorMedix crushed after warning on cash - Seeking Alpha
seekingalpha.com - March 18 at 4:19 PM
nasdaq.com logoMid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher
www.nasdaq.com - March 17 at 4:02 PM
us.rd.yahoo.com logoCorMedix Inc. Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
us.rd.yahoo.com - March 17 at 4:02 PM
biz.yahoo.com logoCORMEDIX INC. Files SEC form 8-K, Results of Operations and Financial Condition
us.rd.yahoo.com - March 17 at 4:02 PM
marketwatch.com logoCorMedix's stock plunges after warning that it may run out of cash
us.rd.yahoo.com - March 17 at 4:02 PM
americanbankingnews.com logoCorMedix Inc. (CRMD) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - March 13 at 8:23 AM
finance.yahoo.com logoCorMedix Inc. to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Business Update
finance.yahoo.com - March 10 at 5:32 PM
biz.yahoo.com logoCORMEDIX INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - March 3 at 4:30 PM
finance.yahoo.com logoCorMedix Inc. Appoints John L. (Jack) Armstrong to Senior Leadership Team
finance.yahoo.com - March 2 at 10:15 AM
finance.yahoo.com logoCorMedix Inc. Announces New Appointments to Senior Leadership Team - Yahoo Finance
finance.yahoo.com - February 2 at 4:53 PM
us.rd.yahoo.com logoCorMedix Inc. Announces New Appointments to Senior Leadership Team
us.rd.yahoo.com - February 1 at 4:51 PM
us.rd.yahoo.com logo8:45 am Cormedix names Robert W. Cook as CFO and Judith R. Abrams, MD., FRCPC as Chief Medical Officer
us.rd.yahoo.com - February 1 at 4:51 PM
finance.yahoo.com logoIs the Options Market Predicting a Spike in CorMedix (CRMD) Stock?
finance.yahoo.com - January 18 at 4:50 PM
finance.yahoo.com logoCorMedix Inc. Announces Dismissal of Shareholder Derivative Action Lawsuit and Stipulation to Forego Appeal
finance.yahoo.com - January 9 at 5:38 PM
finance.yahoo.com logoCorMedix to Present at Biotech Showcase 2017
finance.yahoo.com - January 5 at 5:04 PM

Social

This page was last updated on 5/27/2017 by MarketBeat.com Staff